{
    "clinical_study": {
        "@rank": "10112", 
        "arm_group": [
            {
                "arm_group_label": "Telotristat etiprate", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of telotristat etiprate followed by a 7-day washout."
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of moxifloxacin followed by a 7-day washout."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo with a 7-day washout to follow."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate that telotristat etiprate does not differ from\n      placebo in the mean change from Baseline QT interval corrected for heart rate."
        }, 
        "brief_title": "A Thorough QT Study of Telotristat Etiprate", 
        "condition": "QT Interval", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult males or females \u226518 to \u226455 years of age (inclusive) at the time of\n             Screening\n\n          -  Body mass index \u226518 to \u226432 kg/m2 at Screening\n\n          -  Vital signs (after at least 5 minutes resting in a supine position) at Screening\n             which are within the following ranges:  Systolic blood pressure 90 to 140 mm Hg,\n             Diastolic blood pressure 50 to 90 mm Hg, heart rate 45 to 100 beats per minute (bpm)\n\n          -  Clinical laboratory evaluations (including clinical chemistry panel [fasted at least\n             10 hours], complete blood count, and urinalysis [UA]) within the reference range for\n             the test laboratory, unless deemed not clinically significant by the Investigator\n\n          -  Able to tolerate prolonged periods of quiet, motionless, supervised rest\n\n          -  Willing to adhere to the prohibitions and restrictions specified in this protocol\n\n          -  Able to comprehend and willing to sign an Informed Consent Form\n\n        Exclusion Criteria:\n\n          -  Presence of clinically significant physical, laboratory, or ECG findings at Screening\n             that, in the opinion of the Investigator or Sponsor, may interfere with any aspect of\n             study conduct or interpretation of results\n\n          -  >30 premature ventricular beats per hour on the Holter ECG monitoring at Day -1 of\n             Period 1 (monitored at the clinic via telemetry)\n\n          -  History of additional risk factors for torsade de pointes or the diagnosis or\n             suggestion of a family history of short QT syndrome or long QT syndrome\n\n          -  History of renal disease or significantly abnormal kidney function tests\n\n          -  History of hepatic disease or significantly abnormal liver function tests\n\n          -  History of any clinically significant psychiatric, renal, hepatic, pancreatic,\n             cardiovascular, neurological, or gastrointestinal abnormality\n\n          -  Concurrent conditions that could interfere with safety and tolerability measurements\n\n          -  Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus\n             antibody) or positive human immunodeficiency virus antibody screens\n\n          -  Use of tobacco, use of medications, or history of any disease or condition that might\n             interfere with the conduct of the study in the opinion of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155205", 
            "org_study_id": "LX1606.1-105-NRM", 
            "secondary_id": "LX1606.105"
        }, 
        "intervention": [
            {
                "arm_group_label": "Telotristat etiprate", 
                "description": "1500 mg telotristat etiprate (six 250 mg tablets)", 
                "intervention_name": "Telotristat etiprate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "400 mg moxifloxacin (one 400 mg tablet)", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "Lexicon Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study", 
        "overall_contact": {
            "last_name": "Mike Kelly, Clinical Trial Manager", 
            "phone": "281-863-3026"
        }, 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Suman Wason, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change from baseline QT interval corrected for heart rate", 
            "safety_issue": "Yes", 
            "time_frame": "Days 1-3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "52 days"
            }, 
            {
                "measure": "Plasma concentration of telotristat etiprate", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}